Tumour	B-Cancer
angiogenesis	O
:	O
its	O
mechanism	O
and	O
therapeutic	O
implications	O
in	O
malignant	B-Cancer
gliomas	I-Cancer
.	O

Angiogenesis	O
is	O
a	O
key	O
event	O
in	O
the	O
progression	O
of	O
malignant	B-Cancer
gliomas	I-Cancer
.	O

The	O
presence	O
of	O
microvascular	B-Tissue
proliferation	O
leads	O
to	O
the	O
histological	O
diagnosis	O
of	O
glioblastoma	B-Cancer
multiforme	I-Cancer
.	O

Tumour	B-Cancer
angiogenesis	O
involves	O
multiple	O
cellular	B-Cell
processes	O
including	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
,	O
migration	O
,	O
reorganisation	O
of	O
extracellular	B-Cellular_component
matrix	I-Cellular_component
and	O
tube	B-Tissue
formation	O
.	O

These	O
processes	O
are	O
regulated	O
by	O
numerous	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
growth	O
factors	O
.	O

Angiogenesis	O
inhibitors	O
have	O
been	O
developed	O
to	O
interrupt	O
the	O
angiogenic	O
process	O
at	O
the	O
growth	O
factor	O
,	O
receptor	O
tyrosine	O
kinase	O
and	O
intracellular	B-Immaterial_anatomical_entity
kinase	O
levels	O
.	O

Other	O
anti	O
-	O
angiogenic	O
therapies	O
alter	O
the	O
immune	O
response	O
and	O
endogeneous	O
angiogenesis	O
inhibitor	O
levels	O
.	O

Most	O
anti	O
-	O
angiogenic	O
therapies	O
for	O
malignant	B-Cancer
gliomas	I-Cancer
are	O
in	O
Phase	O
I	O
/	O
II	O
trials	O
and	O
only	O
modest	O
efficacies	O
are	O
reported	O
for	O
monotherapies	O
.	O

The	O
greatest	O
potential	O
for	O
angiogenesis	O
inhibitors	O
may	O
lie	O
in	O
their	O
ability	O
to	O
combine	O
safely	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O

